Summary of WHO classifications in MDS by diagnosis source
| Diagnosis source . | MDS . | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Total . | MDS-SLD . | MDS-RSSLD . | MDS-MLD . | MDS-RSMLD . | MDS-EB1 . | MDS-EB2 . | MDS isolated del(5q) . | MDS-U . | |
| Original local diagnosis | 264 | 23 (9%) | 13 (5%) | 48 (18%) | 34 (13%) | 37 (14%) | 33 (13%) | 12 (5%) | 64 (24%) |
| Validated local diagnosis | 255 | 22 (9%) | 17 (7%) | 51 (20%) | 33 (13%) | 42 (16%) | 35 (14%) | 13 (5%) | 42 (16%) |
| Final study diagnosis | 266 | 14 (5%) | 17 (6%) | 72 (27%) | 46 (17%) | 50 (19%) | 40 (15%) | 12 (5%) | 15 (6%) |
| Diagnosis source . | MDS . | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Total . | MDS-SLD . | MDS-RSSLD . | MDS-MLD . | MDS-RSMLD . | MDS-EB1 . | MDS-EB2 . | MDS isolated del(5q) . | MDS-U . | |
| Original local diagnosis | 264 | 23 (9%) | 13 (5%) | 48 (18%) | 34 (13%) | 37 (14%) | 33 (13%) | 12 (5%) | 64 (24%) |
| Validated local diagnosis | 255 | 22 (9%) | 17 (7%) | 51 (20%) | 33 (13%) | 42 (16%) | 35 (14%) | 13 (5%) | 42 (16%) |
| Final study diagnosis | 266 | 14 (5%) | 17 (6%) | 72 (27%) | 46 (17%) | 50 (19%) | 40 (15%) | 12 (5%) | 15 (6%) |
Diagnosis of MDS was based on the WHO (2016) classification. Total represents the number of participants assigned to MDS for the given assignment source. Denominator in percentage represents the number participants assigned to MDS for the given assignment source.
MDS-EB1, MDS with excess blasts 1 (peripheral blood: 2%-4%; bone marrow: 5%-9% blasts); MDS-EB2, MDS with excess blasts 2 (peripheral blood: 5%-10%; bone marrow: 10%-19% blasts); MDS isolated del(5q), MDS with isolated del(5q); MDS-MLD, MDS with multilineage dysplasia; MDS-RSMLD, MDS with ring sideroblasts and multilineage dysplasia; MDS-RSSLD, MDS with ring sideroblasts and single lineage dysplasia; MDS-SLD, MDS with single lineage dysplasia; MDS-U, MDS unclassifiable.